The Oncomine Comprehensive Panel and Oncomine Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) Test are advanced genomic profiling assays used in the field of oncology to aid in the personalized treatment of cancer. Conducted at DNA Labs UAE, these tests are designed to identify a wide array of genetic mutations, alterations, and biomarkers across various cancer types.
The Oncomine Comprehensive Panel focuses on analyzing a broad set of genes known to be involved in cancer progression and response to treatments. This helps in pinpointing specific genetic changes in a patient's tumor, enabling healthcare providers to tailor treatment strategies based on the unique genetic makeup of the cancer.
The Oncomine TMB and MSI Test complements this by measuring the tumor mutation burden and the microsatellite instability in the cancer cells. TMB is an indicator of the number of mutations within the genome of a tumor, which can predict response to immunotherapy. MSI status is a marker for defects in the DNA repair mechanisms, also informing treatment choices, particularly with immunotherapy.
Offered at a cost of 21000 AED, these tests at DNA Labs UAE represent a significant investment in personalized cancer care, allowing for more targeted and potentially effective treatments. By combining the insights from both the comprehensive panel and the TMB and MSI tests, oncologists can make informed decisions to optimize patient outcomes.
The Amyloid Protein Identification Test is a specialized diagnostic procedure conducted to detect the presence of amyloid proteins in the body. Amyloid proteins are abnormal proteins that can accumulate in tissues and organs, leading to a group of diseases known as amyloidosis. These diseases can affect various parts of the body, including the heart, kidneys, liver, and nervous system, impairing their function.
This test is particularly crucial for individuals who exhibit symptoms suggestive of amyloidosis or those with a family history of the condition. Early detection through the Amyloid Protein Identification Test can facilitate timely intervention, potentially improving patient outcomes.
The test involves collecting a sample from the patient, which is then analyzed in a laboratory setting to identify the presence and type of amyloid proteins. This information is vital for determining the appropriate course of treatment.
Conducted at DNA Labs UAE, a leading facility known for its advanced diagnostic technologies and expert medical staff, the test ensures accuracy and reliability. The cost of the Amyloid Protein Identification Test at DNA Labs UAE is 24,570 AED. While the price might seem high, the test's potential to significantly impact patient care and treatment planning makes it a valuable diagnostic tool in managing amyloidosis.
The Oncopro NCCN Lung Cancer Panel Test, available at DNA Labs UAE, is a cutting-edge diagnostic tool designed to aid in the personalized treatment of lung cancer. This comprehensive test, priced at 23,400 AED, employs next-generation sequencing technology to analyze a patient's tumor sample for specific genetic mutations and biomarkers identified by the National Comprehensive Cancer Network (NCCN) guidelines as relevant to lung cancer care. By pinpointing these unique genetic alterations, the test enables healthcare providers to tailor treatment strategies to the individual patient, potentially improving outcomes and reducing the likelihood of unnecessary side effects. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a significant advancement in the precision medicine approach to lung cancer treatment, offering hope for more effective and personalized care.
The "Hepatitis C Viral RNA Genotype 1 NS5a Drug Resistance Test" is a specialized diagnostic procedure designed to detect resistance mutations in the NS5a region of the hepatitis C virus (HCV) genotype 1. This test is particularly crucial for tailoring the most effective antiviral therapy for individuals infected with HCV, as resistance mutations can significantly impact the efficacy of treatment regimens. The test involves analyzing the viral RNA to identify specific mutations within the NS5a protein, which plays a key role in the virus's replication process and its resistance to NS5a inhibitor drugs.
Given the complexity and precision required for this test, it is performed at specialized laboratories equipped with advanced molecular diagnostic technologies. In the UAE, DNA Labs UAE is one of the facilities offering this cutting-edge test, ensuring high accuracy and reliability in the results. The cost for undergoing the Hepatitis C Viral RNA Genotype 1 NS5a Drug Resistance Test at DNA Labs UAE is 12,000 AED. This investment is crucial for optimizing the management and treatment of HCV, particularly for patients with genotype 1, the most common and often the most challenging to treat variant of the virus. By identifying the presence of drug resistance mutations, healthcare providers can make informed decisions on the most appropriate and effective treatment strategies, potentially improving patient outcomes and reducing the risk of treatment failure.
The "Can Assist Breast Test" is a specialized diagnostic procedure offered by DNA Labs UAE, designed to evaluate the risk of breast cancer by analyzing genetic markers. This test, priced at 15,680 AED, utilizes advanced genetic sequencing technologies to assess the individual's susceptibility to breast cancer. It examines specific DNA segments for mutations and variations that are known to increase the risk of developing the disease. By providing personalized risk assessment, the "Can Assist Breast Test" aids in early detection and enables patients and healthcare providers to make informed decisions about preventive measures and tailored screening schedules. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a significant advancement in personalized medicine and cancer prevention strategies.
The "Oncopro 350 Gene TMB and MSI Profile Test" is a sophisticated diagnostic tool available at DNA Labs UAE, designed to provide comprehensive insights into the genetic profile of a patient's cancer. Priced at 15,210 AED, this test screens for mutations across 350 cancer-related genes, alongside assessing Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) status. These metrics are crucial for understanding the behavior of cancer at a molecular level, guiding personalized treatment strategies. The TMB evaluation helps in determining the likelihood of response to immunotherapy, while MSI status can indicate susceptibility to certain types of cancer treatments. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a critical step towards tailored cancer care, offering hope for more effective and targeted therapy options.
The Oncopro Tumor Mutation Burden (TMB) Test is a cutting-edge diagnostic tool available at DNA Labs UAE, designed to assess the number of mutations within a tumor's DNA. This test plays a crucial role in the field of oncology, as the Tumor Mutation Burden is a biomarker that can predict how well a patient might respond to certain immunotherapies. By evaluating the quantity of mutations, the test can help oncologists tailor more effective and personalized treatment plans for patients with various types of cancer.
The test involves a comprehensive analysis of the tumor tissue to quantify the mutation burden, providing valuable insights into the tumor's behavior and its potential response to treatment. This information is pivotal for determining the suitability of immunotherapy, which works by empowering the patient's immune system to recognize and combat cancer cells more effectively.
Administered at DNA Labs UAE, a facility known for its advanced diagnostic technologies and precision medicine, the Oncopro TMB Test is available for a cost of 14,040 AED. This investment can be a crucial step for patients seeking personalized cancer therapy options, offering a beacon of hope for improved treatment outcomes by leveraging the power of genetic insights to combat cancer.
The "HLA Pre-Transplant Workup Sensitized Recipient Panel 4 Test" is a specialized diagnostic procedure conducted at DNA Labs UAE, designed to evaluate potential transplant recipients for sensitization to human leukocyte antigens (HLA). This test is crucial for identifying individuals who have developed antibodies against HLA, which can significantly impact the success rate of organ transplants. Sensitization can occur due to previous transplants, blood transfusions, or pregnancies, making it essential to assess the compatibility between donor and recipient to minimize the risk of organ rejection.
The test involves a comprehensive analysis of the recipient's immune response to various HLA antigens, providing invaluable information for the medical team to make informed decisions regarding transplantation strategies. The cost of this detailed and critical assessment is 14,040 AED, reflecting the sophisticated technology and expertise required to conduct the test and interpret its results. Conducted at DNA Labs UAE, a facility known for its state-of-the-art technology and highly qualified professionals, this test is a vital step in the pre-transplant evaluation process, ensuring the highest possible success rates for organ transplants by identifying and addressing potential challenges related to HLA sensitization.
The Oncomine Comprehensive Assay Test, available at DNA Labs UAE for a cost of 13,740 AED, is a cutting-edge, next-generation sequencing (NGS) test designed to detect genetic mutations and alterations in cancer patients. This comprehensive assay is capable of analyzing both DNA and RNA from solid tumors to identify a wide array of genetic variants across multiple cancer types. By pinpointing specific mutations, the Oncomine Comprehensive Assay aids oncologists in making informed decisions about personalized treatment options, including targeted therapies and clinical trial eligibility. Conducted in a state-of-the-art facility, DNA Labs UAE ensures precise and reliable results, supporting the advancement of precision medicine in cancer care.
Carrier screening tests are genetic tests designed to determine whether an individual is a carrier of specific genetic disorders. These tests are particularly important for couples planning to have children, as they can help identify the risk of passing on genetic conditions to their offspring. The carrier screening test at DNA Labs UAE is comprehensive, offering insights into a wide array of genetic disorders that could potentially affect future generations.
The cost of the carrier screening test at DNA Labs UAE is 11,400 AED. This investment allows prospective parents to make informed decisions about their family planning, armed with knowledge about their genetic makeup and potential risks. The testing process involves collecting a small sample of DNA, typically through a blood draw or a cheek swab, which is then analyzed in the lab for genetic markers associated with various inherited conditions.
DNA Labs UAE utilizes advanced genetic testing technologies to provide accurate and reliable results. The screening covers a broad spectrum of genetic disorders, ensuring that individuals have a comprehensive understanding of their carrier status. With this information, couples can seek genetic counseling and consider their options for family planning with greater confidence and peace of mind.
